COBENFY
Total Payments
$8.9M
Transactions
15,709
Doctors
9,055
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $8.9M | 15,709 | 9,055 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.4M | 137 | 71.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.4M | 493 | 15.7% |
| Food and Beverage | $592,270 | 12,885 | 6.6% |
| Travel and Lodging | $343,912 | 755 | 3.9% |
| Consulting Fee | $84,994 | 38 | 1.0% |
| Honoraria | $63,378 | 18 | 0.7% |
| Education | $39,356 | 1,382 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $1,100 | 1 | 0.0% |
Payments by Type
Research
$6.4M
137 transactions
General
$2.5M
15,572 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1) | E.R. Squibb & Sons, L.L.C. | $2.8M | 0 |
| An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | E.R. Squibb & Sons, L.L.C. | $2.6M | 0 |
| Phase III OLE of KarXT in Adjuct Schiz (ARISE 2) - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia | E.R. Squibb & Sons, L.L.C. | $855,420 | 0 |
| Phase II Predementia AD | E.R. Squibb & Sons, L.L.C. | $58,424 | 0 |
| Phase III Safety and Efficacy of KarXT in Acute Bipolar (Monotherapy) #1 | E.R. Squibb & Sons, L.L.C. | $42,768 | 0 |
| A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) | E.R. Squibb & Sons, L.L.C. | $39,669 | 0 |
| Ph III Open Label Study to evaluate long term safety and efficacy of KarXT (EMERGENT-5) | E.R. Squibb & Sons, L.L.C. | $967.31 | 0 |
Top Doctors Receiving Payments for COBENFY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Pittsburgh, PA | $6.4M | 164 |
| , MD | Psychiatry | Durham, NC | $70,589 | 62 |
| , MD | Psychiatry | Lewisville, TX | $64,596 | 59 |
| , MD, MPH | Psychiatry | Pomona, NY | $54,995 | 54 |
| Michael Saribalas | Psychiatry | Cleveland, OH | $47,422 | 40 |
| , MD | Psychiatry | Bellflower, CA | $46,993 | 49 |
| , MD | Psychiatry | Lakewood Ranch, FL | $46,465 | 44 |
| , M.D | Psychiatry | Bloomfield Township, MI | $40,106 | 33 |
| , APRN | Psychiatric/Mental Health | Baltimore, MD | $39,055 | 53 |
| , M.D | Psychiatry | New York, NY | $38,342 | 36 |
| , M.D., PH.D | Specialist | El Segundo, CA | $36,189 | 32 |
| , M.D | Psychiatry | Exeter, NH | $34,653 | 27 |
| , MD | Psychiatry | Chicago, IL | $34,405 | 38 |
| , M.D | Psychiatry | Gainesville, GA | $33,926 | 36 |
| , M.D | Professional | Wyomissing, PA | $33,792 | 37 |
| Larry Lambertson | Psychiatry | Kendallville, IN | $33,371 | 29 |
| , M.D | Psychiatry | Irvine, CA | $31,355 | 27 |
| , MD | Psychiatry | Cincinnati, OH | $31,033 | 28 |
| , M.D., PH.D | Psychiatry | Muskegon, MI | $30,626 | 20 |
| , M.D | Psychiatry | San Diego, CA | $29,896 | 28 |
| , M.D | Addiction Medicine | South Miami, FL | $29,588 | 28 |
| , MD | Psychiatry | Norwalk, CT | $29,361 | 15 |
| , MD | Psychiatry | Staten Island, NY | $28,637 | 29 |
| , PMHNP-BC | Psychiatric/Mental Health | Hillsboro, OR | $28,626 | 33 |
| , M.D | Psychiatry | Erie, PA | $28,308 | 39 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $8.9M
- Total Doctors 9,055
- Transactions 15,709
About COBENFY
COBENFY is a drug associated with $8.9M in payments to 9,055 healthcare providers, recorded across 15,709 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2024 to 2024. In 2024, $8.9M was paid across 15,709 transactions to 9,055 doctors.
The most common payment nature for COBENFY is "Unspecified" ($6.4M, 71.7% of total).
COBENFY is associated with 7 research studies, including "Phase III Efficacy and Safety of KarXT in Adjuct Schiz (ARISE 1)" ($2.8M).